The Role of Macrophages in Regulating Inflammation by Oxidative Burst by Pizzolla, Angela
 
From the DEPARTMENT OF MEDICAL BIOCHEMISTRY AND 
BIOPHYSICS 
Karolinska Institutet, Stockholm, Sweden 
 
 
 
 
 
THE ROLE OF MACROPHAGES IN REGULATING 
INFLAMMATION BY OXIDATIVE BURST 
 
 
 
Angela Pizzolla 
 
 
 
 
 
 
 
 
 
 
 
 
Stockholm 2011  
  
Cover page: photo by Gunnar Pippel 
All previously published papers are reproduced with permission from the publisher. 
Published by Karolinska Institutet and printed by Laserics Digital Print AB. 
Landsvägen 65, Sundbyberg, Sweden 
© Angela Pizzolla, 2011 
ISBN 978-91-7457-559-0
 
 
 
 
 
 
 
 
To my past and present colleagues, mice and men 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(G.Renee Guzlas in (1)) 
 
 
 
“Science is the quest for truth. But the truth is not certain truth.” 
(Sir Karl Popper, All life is problem solving) 
 
 
“It is not the possession of knowledge, of irrefutable truth, that makes the scientist,  
but the persistent and recklessly critical quest for truth.” 
(Sir Karl Popper, The logic of scientific discovery) 
 
ABSTRACT 
The production of reactive oxygen species (ROS) through a process called oxidative 
burst is an essential defence mechanism against pathogens. In phagocytes, such as 
neutrophils and macrophages, the NADPH oxidase 2 (NOX2) complex is the main 
source of ROS. Genetic alterations in any of the components of the NOX2 complex that 
impair the ROS production are at the origin of a condition called chronic 
granulomatous disease (CGD), characterized by recurrent life threatening bacterial and 
fungal infections. Recently, natural occurring mutations in Ncf1, a regulatory 
component of the NOX2 complex, were described to compromise the protein function 
and to increase arthritis severity in rats and mice. Macrophages are phagocytes that 
express NCF1 and are able to kill pathogens. At the same time, they are antigen-
presenting cells known to play an important role in arthritis. We therefore hypothesized 
that expression of NCF1 in macrophages would have an impact on the immune 
response during arthritis and bacterial infections. The aim of the studies presented in 
this thesis is to evaluate the influence of NCF1 expressed by macrophages on 
development of arthritis and resolution of bacterial infections. 
 
Using transgenic mouse models we could describe a role for macrophages in both 
priming and activation of arthritogenic T cells. In a first transgenic mouse, expression 
of functional NCF1 restricted to macrophages reduced arthritis severity, priming of Th1 
T cells and T cell proliferation, therefore limiting the T cell-dependent autoimmune 
outbreak. In a second transgenic mouse strain, where macrophages were the only cells 
expressing the arthritis-prone MHC class II Aq molecule, macrophages could prime 
arthritogenic T cells and mediate arthritis development, but only in NCF1 deficient 
setting. We could conclude that ROS production by macrophages is important in 
determining the activation state of T cells and in regulating the severity of arthritis. 
As in the human CGD situation, mice carrying the Ncf1 mutation were more 
susceptible to spontaneous and induced bacterial infections. Using the transgenic 
mouse where macrophages expressed the functional NCF1, we observed that 
macrophage-derived ROS effectively protected mice from bacterial infections, a 
function believed to be executed mainly by neutrophils. 
Finally, we tested a new model of arthritis where the disease was induced with a 
peptide of a glycolytic enzyme. We found that the symptoms and pathogenesis of the 
disease resembled the one of the most common arthritis model, collagen-induced 
arthritis, which is induced with the full collagen protein. Both diseases are dependent 
on an intact adaptive immune system and their severity is influenced by Ncf1. We were 
also able to identify one of the important residues causing the peptide’s arthritogenicity. 
 
In summary, our data highlight the crucial role of NCF1, and consequently of NOX2 
complex, in regulating both innate and adaptive immune responses. NCF1-dependent 
ROS in macrophages was important during both phagocytosis and antigen presentation, 
resulting in clearance of bacterial infection and suppression of chronic inflammation. 
These findings will facilitate further investigations of the molecular pathways through 
which ROS influence arthritis pathogenesis and hopefully lead to identification of new 
therapeutic targets. 
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THE IMMUNE SYSTEM IN A NUTSHELL 
The immune system has the vital task to protect the body from external and internal 
dangers that threaten the health and functionality of the organism. All pathogens 
(viruses, bacteria, yeasts and worms) that come from outside the body are considered 
external dangers. Internal dangers are malignant cells that develop during cancer. 
Internal and external dangers share the capacity to colonize the body and to utilize its 
resources in order to expand, ultimately leading to the death of the host organism. The 
immune system has evolved several strategies to fight threats that come in very 
different sizes and shapes and that colonize different compartments of the body. The 
first line of defence against intruders is the physical barrier provided by the skin and the 
mucous membranes, which separate the body from the environment and are equipped 
with antimicrobial compounds. Just behind these doors, an efficient and fast machinery 
is waiting, ready to shoot, to kill pathogens and remove infected cells: the innate 
immune system. The innate immune system is so called because it does not change 
during the lifetime and provides non-specific protection. Innate immunity comprises 
different types of cells: the phagocytes (literally: eating cells) that eat up pathogens; the 
natural killer cells that directly kill infected cells; mast cells, basophils and eosinophils 
that release toxic substances; a set of molecules, the complement system, that perforate 
or tag an invader. One of the weapons used by the innate immune cells to kill 
pathogens is reactive oxygen species (ROS). These derivatives of oxygen react very 
quickly with biological molecules and irreversibly damage them. ROS are produced 
mainly by two types of phagocytes, neutrophils and monocytes. Defects in the 
production of ROS lead to recurrent and life threatening infection and chronic 
inflammation: a disease called chronic granulomatous disease (CGD) (2). In paper III 
of this thesis it will be shown that monocytes alone can protect the organism from 
bacterial infections by producing ROS. 
Often the action of the innate immune system alone is not sufficient to eliminate the 
threat, therefore another system, the adaptive immune system, gets called to arms. 
The adaptive immune system confers specific protection, tailor-made for the 
characteristics of the pathogen. Two cell types constitute the adaptive immune system, 
T cells and B cells, also called lymphocytes. They share the capacity of randomly 
modifying genes, via rearrangements and mutations, in order to create unique 
molecules that can bind a vast number of pathogens never encountered before in the life 
of the host. Two subtypes of phagocytes, namely macrophages and dendritic cells, 
activate T cells by presenting them pieces of eaten pathogens called antigens. Antigens 
are bound to special molecules called major histocompatibility complex (MHC) on the 
surface of phagocytes forming antigen-MHC complex. Activated T cells can either kill 
the infected cells directly or help B cells to produce antibodies, which will then assist 
the innate immune system in performing its task. After activation, memory T cells and 
B cells remain in the host for the rest of its life and are quickly reactivated upon re-
infection. The activation of the innate and adaptive immune system leads to 
inflammation that needs to be limited in space and time not to permanently damage the 
host. 
Due to the random generation of molecules that recognize the antigen-MHC complex, 
T cells have to be stringently selected to recognize the MHC of the host, but only in 
combination with foreign antigens and not in combination with pieces of proteins from 
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the host (autoantigens). This selection is not completely stringent, so cells that can 
recognize autoantigens are present in the body. These cells are called autoreactive. 
Several mechanisms make sure that autoreactive cells are eliminated or silenced in a 
process called tolerization. Nevertheless, it is still possible that some autoreactive T 
cells and B cells escape all the checkpoints and get activated. Then autoimmunity 
arises, a condition where the body attacks itself. About 5% of the world population 
suffers from autoimmune diseases, some of which are limited to one organ, as multiple 
sclerosis, diabetes or thyroiditis, while some others are systemic as systemic lupus 
erythematosus or rheumatoid arthritis (RA) (3).  
RA symptoms can vary and it is considered a syndrome more than a single disease. It is 
characterized by chronic inflammation in the joints and affects about 1% of the 
population (4). RA is a complex disease where genetic and environmental factors 
interact, making it difficult to identify exactly which factors have an impact on the 
disease development just by studying the heterogeneous human situation. Therefore the 
use of animal models, where the environment and/or the genetic background can be 
tightly regulated, allowed remarkable advances in the study of RA. Using a rat models 
for RA, a gene that regulates arthritis severity has been identified (5). The gene is Ncf1, 
a regulatory component of the NADPH oxidase complex, which produces ROS in 
phagocytes. The most renowned function of ROS is its antimicrobial activity but it is 
also known as a signalling molecule. Recently more and more evidence has shown a 
role of ROS in regulating the adaptive immune response. After the role of Ncf1 was 
confirmed in a mouse model of arthritis (6), the aim is now to understand which 
pathways are affected by this gene. In this thesis, three papers focus on investigating 
the role of Ncf1 in activation of T cells, a crucial cell type in arthritis, using different 
mouse models of the disease. 
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RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting peripheral joints, 
most commonly hands, feet and elbows. It is characterized by joint swelling and pain 
that eventually lead to destruction of the tissue and functional disability. RA is 
associated with lower life expectancy and high risk of developing other disorders 
(comorbidity), especially cardiovascular diseases and other autoimmune diseases (3, 4, 
7). Women are more frequently affected than males and the overall prevalence on the 
total population is about 1% in developed countries (4). The disease can manifest at any 
age with a peak of onset at 50 years of age. It is considered to be an autoimmune 
disease due to the presence of T cells and B cells specific for autoantigens, like type II 
collagen (CII) and citrullinated proteins (8-12). The B cell response is best 
characterized for its production of autoantibodies as anti-IgG called rheumatoid factor 
(RF) and anti-citrullinated proteins antibodies (ACPAs) that arise years before disease 
manifestation (13-15). As the symptoms of RA are similar to other inflammatory 
arthritidies a set of criteria have been established to ensure correct diagnosis (16). 
These criteria have recently been updated by the American College of Rheumatology 
and the European League Against Rheumatism (17). They take into account the 
number of joints affected, the presence of RF or ACPAs, acute phase reactants and the 
duration of the symptoms. The criteria are intended to identify RA at an early stage to 
be able to intervene with proper treatment as early as possible and break the disease 
progression. No cure for RA is available so far. 
 
DISEASE PATHOLOGY 
The exact pathological mechanisms that drive RA are still unknown. Some insights 
have been gained from comparing the cellular and molecular components of inflamed 
joints with healthy ones. The most affected joints in RA are synovial joints, as knees, 
fingers and hips. They constitute the junction between two or more bones and are 
characterized by a space between the bones, called synovial cavity, filled with synovial 
fluid. The junction of the two bones is surrounded by the articular capsule, which seals 
the synovial fluid from the surrounding tissue. The inner layer of the articular capsule is 
called synovial membrane (or synovium). It secretes the synovial fluid and supplies 
nutrients to the cartilage that covers the bones. During RA, inflammation of the 
synovium occurs (synovitis). The macrophage-like and fibroblast-like cells that 
compose the synovium proliferate and produce excess of synovial fluid together with 
pro-inflammatory cytokines, chemokines, matrix metalloproteinases, growth factors 
and even complement proteins and RF (18, 19). All these soluble components actively 
destroy the extracellular matrix by sustaining the proliferation and activation of the 
synovial cells and recruiting new immune cells from the blood stream.  
Both adaptive and innate immune cells are found in the RA synovium. The presence of 
activated and memory CD4+ T cells in the synovium, typical of RA (20), agrees with 
the association of the HLA-DRB1 gene to RA, which points towards the MHC class II 
activation of T cells being a pathogenic mechanism in RA. Several antigen-presenting 
cells (APCs) are present, including B cells, dendritic cells, and macrophages that 
sample the tissue antigens and present them to T cells in lymph nodes (21). The 
formation of ectopic lymphoid follicle-like structures with germinal centers in the 
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synovium is characteristic of RA and may be important in sustaining a local 
inflammation and B cell activation (22). B cells producing autoantibodies have been 
found in the synovium (23). Innate immune cells such as neutrophils and mast cells 
are also recruited to the inflamed synovium and produce cytokines, proteases and ROS 
that collaborate to the inflammatory milieu and to the cartilage destruction. High ROS 
levels have been detected in inflamed tissue and can contribute to the tissue damage 
(reviewed in (24)). New blood vessels are created in the normally avascular synovium, 
a process called neovascularization. Sustained inflammation leads to the formation of a 
tumor-like structure called pannus, formed by macrophages, osteoclasts (cells that 
degrade bone) and fibroblast-like synoviocytes, which destroy bone and cartilage. This 
massive infiltration of cells and fluids causes swelling, pain and erythema. Cartilage, a 
thin layer of extracellular matrix with covers the bones and dampens friction between 
bones, is also infiltrated by immune cells, which destroy and erode the tissue leading to 
permanent joint deformation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Illustrative picture of a healthy joint on top and a RA joint on the bottom. 
Drawing from Universalium 2010 
 
RISK FACTORS 
Both genetic and environmental factors influence the development of RA. 
Genetic predisposition to RA accounts for about 60% of the liability to disease, as 
established in studies with twins (25, 26). The first locus to be associated with RA was 
the Human Leucocyte Antigen (HLA) in 1976 (27), which is the human nomenclature 
for the MHC. Until today HLA is the strongest known genetic factor associated with 
RA. The HLA locus comprises a vast number of genes coding for key molecules in 
antigen presentation. Several alleles of genes encoding for the beta chain of the HLA-
DR molecule confer increased risk of developing RA. The RA-associated alleles were 
found to share a sequence of five amino acids, called the shared epitope (SE), Gln/Arg-
Lys/Arg-Arg-Ala-Ala, in a region of the DRβ chain that contributes to the antigen-
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binding site (28). It has been postulated that the SE allows the presentation of 
arthritogenic peptides to T cells (28). 
The HLA locus contributes to about 30% of the total genetic risk (29), leaving room for 
an influence of other non-HLA genes in the disease. These genes are much harder to 
identify due to their modest effect and their wide spreading in the population. Almost 
30 years later the first non-HLA gene was associated with RA: the peptidylarginine 
deiminase type 4 (PADI4) in 2003, only confirmed in the Japanese population (30). 
PADI4 encodes for the enzymes that modify arginine into citrulline, the target of the 
ACPA autoantibodies. One year later another gene was described as a risk factor for 
RA: the protein tyrosine phosphatase non-receptor, type 22 (PTPN22) (31). A single 
nucleotide polymorphism (SNP) in PTPN22 is associated with several autoimmune 
diseases, including RA. This SNP decreases the responsiveness of T cells and B cells to 
antigen stimulation and alters the numbers of memory T cells and memory B cells (32, 
33). The SNP is thought to impair the selection of lymphocytes, leading to release of 
autoreactive cells into the circulation or lower activity of regulatory T cells (32). 
Thanks to technical advances, several other loci have been associated with RA in the 
last years. Many of them contain genes already known to affect the immunological 
responses, as CTLA4 (34), TRAF1/C5 (35), STAT4 (36) and CD40 (37). For most of the 
associated loci, the causative SNP has not been identified and the current challenge is 
to clarify the molecular mechanisms linking the genes and the disease pathogenesis. 
 
As RA results from the interaction of genes and environment, some environmental 
factors that predispose to disease have been identified. The most studied environmental 
factor is cigarette smoking, identified for increasing risk of RA in 1987 and confirmed 
further in several studies (38). Interestingly an interaction between smoking and the 
HLA-DRB1 SE alleles has been found to increase the risk of developing ACPA-
positive RA (39, 40). Smoking induces citrullination of proteins in the lungs (40) and T 
cells can recognize citrullinated antigens presented on MHC class II and HLA-DRB1 
molecules (Snir et al. ; Ireland et al. 2006). Recently T cells with this specificity have 
been identified in RA patients (9). 
Since long infectious agents have been suspected to be one of the causes of RA 
development, but no conclusive evidence has been shown so far. Immune responses to 
different pathogens have been observed to correlate with RA, including bacteria, such 
as Escherichia coli, Proteus mirabilis and Klebsiella pneumoniae, mycoplasma and 
viruses, such as Epstein–Barr Virus (EBV) and Cytomegalovirus (reviewed in (41)). 
Recently periodontitis, an oral infection, has been associated with RA (42). Peridiontitis 
is often caused by the bacterium Porphyromonas gingivalis that is a unique prokaryote 
with a peculiar capacity to citrullinate human proteins (43). P. gengivalis infections can 
lead to a break in the tolerance to citrullinated antigens and formation of ACPAs also in 
non-RA patients (41). These findings have promoted the hypothesis that P. gingivalis 
infection may be one of the causes for development of RA (44, 45). 
The influence of hormones on RA development is suggested by the fact that women 
are more susceptible than males. Several studies have addressed the influence of 
hormones or the use of oral contraceptives on the risk of developing RA and they 
showed contrasting results, even though most of them conclude that there is no 
association between the use of oral contraceptives and arthritis (38, 46). There is little 
consensus also on the effect of parity and breast-feeding on RA development (47-49). 
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Diet is an important environmental factor. Alcohol consumption was found to decrease 
the risk of developing arthritis in Scandinavian cohorts (50) while meat consumption 
seemed not to alter the risk (51). Dietary anti-oxidatidants have been shown to be 
preventive but not to improve established disease (52). 
A lower socioeconomic status, measured by education and occupational class, has been 
associated with a higher risk of developing RA in Scandinavian countries (53, 54). 
 
In conclusion, in RA, the most influential factors associated with the disease have been 
identified about 30 years ago and confirmed by several studies, such as the HLA locus 
and smoking. A number of other genes and environmental factors that contribute for a 
small percentage to the total risk have been recently identified and are under 
investigation. 
 
TREATMENTS 
Although no cure is available for RA, a wide spectrum of treatments is nowadays in use 
with the main goal of alleviating the symptoms and slowing down disease progression. 
Pharmacological treatments are the most used intervention and will be discussed below. 
Non-pharmacological treatments include physical activity (55) and surgical removal of 
inflamed synovium (56). 
Pharmacological treatment can be divided into three classes of drugs according to their 
mechanism of action. 
Anti-inflammatory drugs and analgesics reduce the pain and the inflammation 
promptly. The anti-inflammatory drugs can be divided into glucocorticoids and non-
steroideal anti-inflammatory drugs (NSAIDs). Glucocorticoids (GCs) are derivatives of 
natural anti-inflammatory hormones and act as potent anti-inflammatory and 
immunosuppressants by regulating the expression of several genes. They can slow 
down disease progression and they are still very extensively used, especially before a 
definite diagnosis of RA. Their side effects however limit prolonged usage (57). 
NSAIDs, as aspirin, diclofenac and ibuprofen control pain by inhibiting prostaglandin 
formation and they are anti-inflammatory but cannot slow disease progression. As pain-
relief also medical use of cannabis has been proven efficient (58). 
Disease-modifying anti-rheumatic drugs (DMARDs) are the first drugs to be 
administered after diagnosis of RA. They act slowly but powerfully in reducing cell 
functions and proliferation thereby affecting the immune system for a long time and 
inhibiting the disease progression. The most used DMARM is Methotrexate (MTX), 
which inhibits cell proliferation, T cell activation and induces apoptosis (59, 60). 
Interestingly the efficiency of this drug is dependent on ROS production in vitro 
(reviewed in (61)).  
If a patient fails to respond to DMARDs, newer drugs called biologic drugs are 
prescribed. These comprise monoclonal antibodies and recombinant proteins that 
specifically target one pro-inflammatory molecule and inhibit or block its action. The 
first biological drug to be launched was a monoclonal antibody against tumor necrosis 
factor alpha (TNF-α), a central cytokine in RA, which is now successfully used, often 
in combination with DMARDs (62). Other monoclonal antibodies that target cytokine 
pathways have recently been described and proven efficient in the treatment of RA 
patients: anti-IL1 and IL-6 receptors (63, 64) and anti-IL15 (65). Other biologics 
directly target adaptive immune cells by depleting them or inhibiting their activation. 
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This is the case for the anti-B cells therapy that uses the anti-CD20 antibody to remove 
B cells (66), or the fusion molecule between cytotoxic T-lymphocyte antigen-4 (CTLA-
4) and immunoglobulin (Ig) (CTLA-4-Ig), which inhibits T-cell activation (67). As the 
biologic drugs inhibit the immune system, they have been reported to increase the risk 
for infectious diseases and cancer. Although a recent meta-analysis did not detect a 
significant increased risk for these pathologies in the short-term after treatment with 
biologics, it highlighted a higher risk for adverse events and emphasized the need of 
long-term safety assessments (68). 
As the need for safe and effective drugs is still very present, other therapeutic strategies 
are under investigation, as well as personalized therapy. 
  8 
ANIMAL MODELS OF RHEUMATOID ARTHRITIS 
As described in the previous chapter, rheumatoid arthritis is a complex disease where 
several genes and environmental factors interact and contribute to the development of 
the pathological condition. To develop effective treatments, understanding of the 
mechanisms that lead to disease is fundamental. Nevertheless, the complexity of the 
disease, the heterogeneity of the human population, in terms of genetic and 
environmental variations, and ethical restrictions complicate the human studies 
enormously. In humans it is almost impossible to study the initial phase of the disease, 
as it is often asymptomatic and occurs over several years. 
To circumvent several of these obstacles, animal models of arthritis are used, most 
often with mice and rats. Animal models allow control and manipulation of the genetic 
background and the environment independently, enabling specific studies of the 
influence of only one or a few elements and the detection of very small effects on the 
disease. The genetic background is controlled using inbred strains, where all 
individuals are genetically identical. By crossing susceptible and resistant strains of 
mice or rats, it has been possible to identify genes that protect from or increase 
susceptibility to disease, such as Ncf1 (5). These genes are not possible to pinpoint in 
humans due to their too small effect or too complex genetic structure. Furthermore, 
today’s technology enables specific alterations at the level of one gene, as for example 
expression of a foreign gene, called transgene, or inhibition of the expression of one 
gene, called knock-out. Similarly, the environment can be controlled by housing the 
rodents in animal houses where food, air, water and pathogen exposure are constant and 
monitored.  
Few strains develop arthritis spontaneously while in most cases the disease needs to be 
induced. The induction is most commonly achieved by injection of substances that 
trigger the immune system, as oils, adjuvants, proteins, bacteria, pathogen components 
or antibodies. Artificial induction allows a time control over the disease and the 
possibility to intervene at different time points of the disease course, so to further 
dissect pathological mechanisms. Despite the availability of several animal models of 
arthritis, each model reflects only some of the kaleidoscopic characteristics of human 
arthritis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Typical mice used for experiments. Image: OAK RIDGE NATIONAL 
LABORATORY 
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In the next paragraphs, I will describe in details three inducible arthritis models that 
have been used in the papers presented in this thesis. Other currently used models 
include the spontaneous arthritis in SKG mice and TNF-α transgenic mice. SKG mice 
carry a mutation in the ZAP70 gene (69). ZAP70 acts as a signalling molecule 
downstream of the TCR (70). The mutation weakens the TCR signal and allows the 
selection of autoreactive T cells (69). The disease develops spontaneously in 
conventional animal houses, but in pathogen-free conditions it needs to be induced by 
injection of yeast extract (71). This observation argues for an infectious component in 
arthritis development. TNF-α transgenic mice overexpress the human TNF-α molecule 
(72): as the arthritis develops only in presence of the genetic modification, it is not fully 
considered as a spontaneous arthritis model. 
 
COLLAGEN INDUCED ARTHRITIS 
Type II collagen (CII) is the most abundant protein in the hyaline cartilage, the type of 
cartilage that surrounds bones in the joints. CII was found to induce arthritis in 
susceptible strains of rodents when injected intradermally in combination with an 
adjuvant (73, 74). The model is called collagen-induced arthritis (CIA) and is one of the 
most used. Disease symptoms appear 3 weeks after immunization with swelling, 
erythema leading to cartilage and bone erosion (73). One of the important factors in 
CIA susceptibility is the MHC class II region: H-2q and H-2r haplotypes confer 
susceptibility to arthritis induced with heterologous CII, while others confer resistance 
(75). Within the MHC class II region, the Aβ gene of q haplotype (Aq) confers 
susceptibility to disease (76). One of the reasons for the susceptibility of the H-2q strain 
and the resistance of the H-2p strain can lye in the higher affinity of the Aq molecule for 
the immunodominant T cell epitope, the CII256-270 peptide, than the Ap molecule (77). 
Both rat (heterologous) and mouse (autologous) CII can induce arthritis in Aq mice 
(78). The rat CII256-270 peptide differs for one amino acid from the mouse CII256-270 
peptide and it binds with higher affinity to the Aq molecule(77). This difference in 
affinity may explain why the rat collagen induces a more severe form of arthritis than 
the mouse one (78). Both innate and adaptive immune systems are important for CIA 
development and their cellular components are present in the inflamed joints (79). 
Among APCs, macrophages but not Langherans dendritic cells can present CII to T 
cells (80). T cells and B cells are essential to induce CIA (81, 82). Both lymphocytes 
are activated against CII epitopes, as found in RA patients (8, 10, 11). In Aq expressing 
mice, the immunodominant T cell epitope has been located between position 256 and 
270 of CII (83). To characterize the T cell response, cytokine production was 
monitored. To prove the importance of cytokines in the disease pathogenesis, cytokines 
were selectively eliminated from the system with the use of genetically modified mice 
or antibody depletion. This led to a complex picture, as cytokines may have several 
redundant roles. A common view today is that Th1 and Th17 cells drive arthritis while 
Th2 cells suppress the symptoms in the CIA model. In CIA B cells produce 
arthritogenic antibodies that are directed towards several epitopes of CII (84, 85). 
Among the innate immunity factors, the complement system has been extensively 
studied and identified as a key player in the disease development (86). Outside the 
classical immune pathways, Ncf1 has been identified as a factor that increases arthritis 
susceptibility and severity in CIA (5, 6). Paper I and II investigate how Ncf1 influences 
T cells activation in CIA. 
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COLLAGEN ANTIBODY INDUCED ARTHRITIS 
Arthritis can be induced by injection of serum from arthritic mice or RA patients (84, 
87, 88). Monoclonal antibodies specific for CII were derived from CII immunized mice 
and injected into naïve mice: the recipient mice developed arthritis and the model is 
then called collagen antibody induced arthritis (CAIA) (85, 89, 90). The onset is rapid 
and arthritis can be seen after 2 days and it resolves after a month, leaving the mice 
healthy. LPS increases disease severity and incidence (90, 91). CAIA is independent of 
MHC class II, T cells and B cells (90, 92), but it requires the presence of neutrophils, 
complement system and FcRγ-chains (92-94). It is therefore a model where the 
activation of the innate immune system is sufficient to induce disease. The 
inflammatory response is triggered by deposition of the antibodies on the cartilage, 
which attracts and activates the complement system, macrophages and neutrophils. It 
allows studying effector pathways of arthritis without involving the priming phase. 
 
K/BXN MODEL AND GLUCOSE-6-PHOSPHATE ISOMERASE INDUCED 
ARTHRITIS 
The K/BxN model is a spontaneous model of arthritis that arises at around 3 weeks of 
age in KRN TCR transgenic mice (recognizing a peptide of bovine RNase on Ak) on 
C57Bl/6 (B6) background, crossed with NOD mice carrying the Ag7 allele (95). As in 
CIA, the adaptive immune system is required for arthritis development (95). In the 
context of Ag7, T cells and B cells recognize a ubiquitously expressed glycolytic 
enzyme, glucose-6-phosphate isomerase (GPI) (96). Serum from arthritic mice can 
transfer disease to naïve mice (97), as well as anti-GPI monoclonal antibodies derived 
from arthritic animals (98). The K/BxN serum transfer model operates through the 
innate immune system (complement, neutrophils, mast cells and macrophages) and FcR 
in a similar fashion to CAIA (99-104). 
 
Immunization with recombinant human (h)GPI protein in complete Freund’s adjuvant 
(CFA) is able to induce arthritis in susceptible strains: DBA/1 or C3H (105, 106). The 
disease depends on both adaptive and innate immunity: T cells, B cells and the right 
MHC allele are necessary to induce the disease, as well as FcγR positive cells and 
monocytes/macrophages (105-108). Antibody treatment directed against IL-17, IL-6, 
TNF-α or blocking CD28 signalling with CTLA-4-Ig ameliorate the disease (106, 109). 
T regulatory cells are important to control the chronicity of arthritis. The disease 
normally resolves about 5 weeks after immunization in DBA/1 mice but it becomes 
chronic in mice depleted for T regulatory cells (108). Recently a pathogenic role of 
IFN-γ receptor in this model of arthritis has been described (110). 
In 2008 a group in Japan identified a peptide of hGPI that could induce disease in 
DBA/1 animals, leading to a cross-reactive response to the murine peptide (111). 
Immunization with the hGPI325-339 peptide induces Th1 and Th17 responses (111). 
However the peptide-induced arthritis is milder than the disease induced by the full 
protein and immunization with the peptide induced lower titers of anti-hGPI antibodies 
than with the full protein (111, 112). In paper IV we investigated the arthritis generated 
by immunization with the hGPI325-339 peptide in C57BL/10.Q mice, which share the H-
2q haplotype with DBA/1 mice. 
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OXIDATIVE BURST 
Oxidative burst (or respiratory burst) is the process of rapid production of reactive 
oxygen species (ROS). ROS comprise a variety of small molecules, which contain an 
oxygen atom and are highly reactive with other molecules. The reactivity is due to the 
oxygen atom being unstable due to lack of electrons and to its strong tendency to 
acquire the missing electrons from other molecules: a process called oxidation. ROS 
are therefore strong oxidizing agents or oxidants and can reversibly or irreversibly 
oxidize almost all biological molecules. The most common ROS, and the enzymes that 
catalyse their formation in biological systems, are illustrated in the figure below. 
Various ROS have different chemical characteristics, as permeability to cell 
membranes, half-life, reactivity and consequently different targets that they can react 
with. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The most common reactive oxygen species in vivo and their catalytic formation. 
•NO: nitric oxide, •NO2: nitrogen dioxide radical, ONOO-: peroxynitrite, •OH, hydroxyl 
radical, NO2-: nitrite ion, HOCl: hypoclorous acid, SCN-: thiocyanate, HOSCN: 
Hypothiocyanous acid, 1O2: singlet oxygen, SOD: superoxide dismutase. Figure modified from 
(113). 
 
In a cell ROS can be produced in several different compartments, where they achieve 
distinct functions. In the mitochondria ROS arise as result of leakage from the electron 
transport chain and have recently been found to contribute to cell signalling (reviewed 
in (114)). In the endoplasmic reticulum ROS are produced during protein folding, in 
particular in conjunction with oxidation of sulfhydryl groups to form disulfide bond, a 
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process mediated by a thioredoxin protein disulfide isomerase (PDI) (115). In this 
compartment NOX4 complex has also been described (116). 
Specialized enzymatic complexes produce the majority of the ROS in the cell: the 
NOX family of NADPH oxidases, comprising of five NADPH oxidase complexes 
(NOX1-5), and two dual oxidase complexes (DUOX1-2) (reviewed in (117)). They 
mediate ROS production over the cell membranes in virtually every cell of the body, 
but their ROS potential, the activation mechanisms as well as their cell and tissue 
distribution vary greatly. Their physiological role spans from pathogen killing to 
signalling. A wide range of pathologies are associated with their dysfunctions, 
including both deficiency and increased activity (reviewed in (117)). The phagocyte 
NOX2 complex is the first identified and most studied complex. It has also been 
studied in different contexts in the investigations illustrated in this thesis. The NOX2 
complex will be described in details in the next paragraphs. 
 
THE NOX2 COMPLEX: STRUCTURE AND REGULATION 
The NOX2 complex is expressed mainly in phagocytes, having the highest expression 
in neutrophils followed by macrophages and dendritic cells (118). Low expression has 
been detected in B cells and T cells (119, 120). Other cells types have also been found 
to express it, as neurons and cardiomyocytes (reviewed in (117)).  
The NOX2 complex is localized in membranes and catalyses the transfer of two 
electrons from intracellular NADPH to two extracellular or luminal oxygen molecules, 
generating superoxide (O2-) (121). In phagocytes the NOX2 complex is present in both 
the plasma membrane and organelles membranes, as phagosomes and granules. The 
NOX2 complex comprises of multiple proteins in addition to the enzymatic core. The 
different protein components were identified and cloned over a decade ago and 
extensive work has been performed to understand the regulation of the complex.  
 
Today the following structure and activation is proposed. The activation of the NOX2 
complex requires of at least five components to be recruited at the membrane and 
assembled together. The catalytic core is constituted by two transmembrane proteins: 
GP91phox (called also NOX2) and P22phox, which together form the cytochrome b558 
complex (122). The two proteins are constitutively associated and P22phox is necessary 
for the stability of GP91phox, since in P22phox-deficient patients no GP91phox protein was 
detectable (123). Four cytosolic proteins are required for full activation of the complex: 
NCF1 (or P47phox), NCF2 (or P67phox), NCF4 (or P40phox) and GTPase Rac. The NCF 
denomination will be used for these proteins throughout this thesis. 
 
Activation of the NOX2 complex requires translocation of the four factors from the 
cytosol to the cytochrome b558 complex in the membrane. The first event of the 
activation is the phosphorylation of NCF1 and the consequent release of its auto-
inhibitory conformation (125). NCF1 can then bind to P22phox and translocate to the 
membrane (126). As NCF1 is bound to NCF2, also NCF2 get translocated to the 
membrane (127). NCF1 activation leads to the translocation of the other cytosolic 
factors, therefore it is considered as the organizer subunit. NCF2 is then able to bind 
GP91phox (128) and activate it, therefore being considered the activator (129). The 
NCF4 subunit is also translocated to the membrane (130). NCF4 seems to be an 
important regulator of the intracellular phagocytosis-induced ROS (131, 132). Finally, 
  13 
the GTPase Rac interacts directly with GP91phox and with NCF2 (133, 134). Rac exists 
as three homologous proteins that participate in several cellular signalling mechanisms. 
When it comes to NOX2 complex activity, Rac1 operates in macrophages while Rac2 
in neutrophils (135, 136). 
 
 
 
Figure 4: NOX2 complex and its activation. Figure modified from (124). 
 
In phagocytes, most of the GP91phox/ P22phox complex is located in intracellular 
compartments at resting state (137). After activation the complex can be functional in 
the same granule, producing intracellular ROS, or it can translocate to the plasma or the 
phagosome membrane as result of the fusion of the organelle were it was stored with 
plasma membranes (137, 138). 
ROS production by the NOX2 complex is mainly regulated by the activation of the pre-
existing proteins, induced transcription being only as minor way to regulate ROS 
production. Some signals, as cytokines and TLR agonists, can prime the complex and 
induce only the first part of the activation: the phosphorylation of NCF1 and its 
translocation to the membrane. This priming will accelerate and amplify the assembly 
of the complex once the activation signal arrives (139). Other signals, as phorbol-12-
myristate-13-acetate (PMA) or formyl-methionyl-leucyl-phenylalanine (fMLF), can 
directly activate the complex (reviewed in (113)). 
 
The human and mouse GP91phox genes are located in the X chromosome, but the genes 
for the other subunits are located in different chromosomes. Their expression is mainly 
constitutive but can be induced by a variety signals, for example by TLR ligands, IFN-γ 
and PMA (140-142). Several compounds can inhibit the formation of ROS by NOX2 
complex, the most common being diphenylene iodonium (DPI), but none of them has 
been proven specific for the complex due to interaction with other pathways and other 
NOX complexes (reviewed in (113)). 
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NCF1 
NCF1 is a cytosolic, non glycosylated protein of about 47 kDa in size (143, 144). It is 
considered to be the organizer subunit of the NOX2 complex because the activator 
subunit NCF2, the small NCF4 subunit, and the GTPase Rac fail to translocate to the 
membrane in neutrophils lacking NCF1 (145). 
NCF1 has a phox domain (PX) that interacts with membrane phospholipids, in 
particular to 3'-phosphorylated phosphatidylinositols, the products of 
phosphotidylinositol 3-kinase. It has two SH3 domains that interact with the C-terminal 
autoinhibitory region (AIR) in resting state but bind to proline-rich regions in the C-
terminus of P22phox in activated state (146). After phosphorylation NCF1 undergoes a 
conformational change and can then bind P22phox and translocate to the plasma 
membrane (147). A proline-rich region at the C-terminus of NCF1 interacts with SH3 
domains in NCF2 (129). 
The Ncf1 gene is encoded on chromosome 5 in mouse and on chromosome 7 in 
humans, but the gene structure differs in the two species as pseudogenes and copy 
number variations of NCF1 are present in the human but not in the mouse genome 
(148-151). The expression is induced by cell differentiation and activation stimuli, as 
TLR ligands, cytokines, glutamine and PMA (140, 142, 152, 153). 
 
 
 
 
 
 
 
 
 
Figure 5: illustrative structure of NCF1 
PX: phox domain, SH3: SRC homology 3 domain, AIR: autoinhibitory domain, PR: proline-
rich domain 
 
ANTIBACTERIAL FUNCTION OF NOX2 COMPLEX AND DISEASE 
IMPLICATIONS 
The NOX2 complex was identified while searching for the molecular dysfunctions 
causing chronic granulomatous disease (CGD), a condition where the patient suffers 
from recurrent and life-threatening infections by bacteria and fungi (154-157). 
Mutations in all the subunits of the complex, including NCF1, have been observed in 
CGD patients (158, 159). Ncf1 knockout mice (Ncf1-/-) are affected by spontaneous 
bacterial infections (160) and therefore they are often used as a mouse model of CGD. 
A similar phenotype has been observed in mice carrying a natural occurring SNP in 
Ncf1 (paper III). The antibacterial and antifungal activity of the complex is due to the 
production of ROS. The superoxide generated by the NOX2 complex can kill the 
pathogen by itself (117). However, the antibacterial activity of ROS is carried manly 
out through activation of several antimicrobial mechanisms that result in the formation 
of toxic compounds or activation of proteases. These mechanisms include: 1) formation 
of other ROS and reactive nitrogen species, either spontaneously or by enzymatic 
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catalysis, as suggested by the fact that CGD phagocytes can recover their killing 
capacity by addition of H2O2 generating system (161); 2) regulation of the pH: 
superoxide being a weak base, it increases the pH of the phagosome allowing optimal 
activity of the proteases in neutrophils (162); 3) activation of ion flux into the 
phagosome, due to an increase in negative charges inside the granule mediated by 
superoxide, which activates proteases (163); 4) induction of apoptosis in infected 
neutrophils and macrophages (164-166). 
 
THE NOX2 COMPLEX IN INFLAMMATION AND RA 
ROS is a double-edged sword: it is essential to kill pathogens, but it can also harm the 
tissue. In inflamed tissues, as RA joints, the NOX2 complex in neutrophils is primed, 
allowing them to produce more ROS and more rapidly (167-169). In these tissues 
increased oxidation of biological molecules and reduced levels of antioxidant system 
are detected (170). These observations led to the belief that high ROS production is 
harmful for the host. 
The other side of the coin is that impairment of ROS production by the NOX2 complex 
is accompanied by excessive inflammation, as observed in CGD patients. The name of 
the disease refers to chronic persistency of granulomata, local inflammations 
characterized by a compact collection of cells, mainly macrophages but also other 
innate immune cells and lymphocytes. A part from infection-derived inflammations, 
CGD patients suffer from a variety of inflammatory conditions and autoimmune 
diseases ((171) and reviewed in (172)). Animal models for CGD, where gp91phox or 
Ncf1 have been knocked-out or mutated, show higher susceptibility to bacterial and 
fungal infections ((160, 173, 174) and paper III), as well as to inflammatory and 
autoimmune diseases ((5, 6, 175, 176) and paper I, II and IV). 
Therefore one of the functions of the NOX2 complex is to dampen inflammation. 
This is achieved through the direct activity of ROS on the resolution of the 
inflammation, i.e. clearing the pathogen causing the inflammation, and through the 
function of ROS as signalling molecules, attenuating pro-inflammatory signals and 
stimulating anti-inflammatory ones. 
The role of NOX2 complex-derived ROS as signalling molecule has been thoroughly 
investigated in the last years. ROS has been found to affect a variety of cellular 
processes: cell growth and death, gene expression, protein activation or inactivation, 
ion channels, calcium signalling and angiogenesis (reviewed in (117)). So far, in 
immune cells, few direct targets of ROS-mediated oxidation have been identified but 
several inflammatory mechanisms have been found affected: they will be discussed in 
the following paragraphs. 
 
For what it concerns gene expression in immune cells, a number of genes involved in 
the inflammatory response are regulated by ROS, including TNF-α (177), interferon 
(IFN)-β pathway (178), transforming growth factor (TGF)-β among others (reviewed in 
(179)). NOX2 complex-derived ROS affects gene expression via transcription factors: 
NF-κB, AP-1 and p53, which have a cysteine residue in their DNA binding site 
(reviewed in (117, 180)). NF-κB is a transcription factor whose activity is involved in 
the expression of immune response (181). NF-κB has also been implicated in 
pathogenesis of RA since up-regulation of NF-κB and of NF-κB regulated genes has 
been observed in the RA synovium (182, 183).  
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Central signalling pathways in immune cells that are regulated by ROS are the ones 
mediated by mitogen-activated protein (MAP) kinases, which are involved in anti-
apoptotic signalling (184), in differentiation and activate transcription via NF-κB 
(reviewed in (117)). 
Cell specific pathways regulated by NOX2-dependent ROS are discussed below. 
 
Antigen presenting cells and neutrophils 
NOX2 complex-dependent ROS production is central in modulating several functions 
of antigen presenting cells (APCs). First, ROS production is part of the physiological 
activation of APCs: NOX2 complex expression and activity is increased after activation 
stimuli, such as TLR ligands (140) and suggested to be reduced after anti-inflammatory 
stimuli such as IL-4 (185). The downstream effects of NOX2 complex-dependent ROS 
production in APCs are multiple. APCs process and present antigen to T cells to 
activate them. In order to produce antigens, proteases degrade proteins in a process that 
is dependent on the pH of the phagosome. Dendritic cells (DCs) with impaired NOX2 
complex show decreased pH and increased antigen degradation, leading to defective 
cross-presentation to CD8+ T cells (186). This effect has not been observed during 
MHC class II-dependent presentation to classical CD4 T cells, the subtype of cells 
considered to be the main players in RA (186, 187). Macrophages derived from the 
gp91phox knock-out mouse, a model for CGD, displayed enhanced phagosomal 
proteolysis and capacity to reduce disulfide bonds compared to wt mice (188), which is 
in line with the observations by Savina et al. (186). No difference between gp91phox 
knock-out and wt mice was detectable when the macrophages were treated with IL-4 
(185). Cytokine production by APCs is another signal important for T cell activation 
helping to shape the quality of the T cell response. Phagocytes from CGD patients 
released lower levels of anti-inflammatory cytokines, such as TGF-β, during 
phagocytosis (166). CGD leukocytes produced higher levels of pro-inflammatory 
cytokines, as TNF-α and IL-6, after TLR or fungal stimulation (189, 190). Also CGD 
neutrophils are hyperresponsive and produce higher levels of both pro-inflammatory 
(IL-8, TNF-α) and anti-inflammatory (IL-10) cytokines after fungal stimulation than 
neutrophils from healthy individuals (191). 
Even B cells express the NOX2 complex, although at lower levels than phagocytes 
(paper I), and they produce ROS upon stimulation via Ig (192), LPS (193) and Epstein-
Barr virus (194). NOX2 complex-dependent ROS production has been suggested to 
have an impact on B cell differentiation and activation (193). 
The expression of the NOX2 complex in APCs has been reported to impact on T cell 
functions in autoimmune, cancer and viral infection settings, where macrophages and 
myeloid derived suppressor cells suppress T cell responses through NOX2 complex 
activity ((195, 196) and paper I and II). 
 
T cells 
Expression of the NOX2 complex and/or autonomous ROS production by T cells is 
still debated, as some studies have reported it while others fail to detect them (120, 197-
199). TCR stimulation induced ROS production in T cells (reviewed in (200)), even 
when the stimuli were MHC molecules carrying the RA associated sequence called 
Shared epitope (201). ROS production by T cells is very minimal compared to that of 
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myeloid cells (202). Several T cell signalling pathways and functions are however 
regulated by redox balance, but their dependency on NOX2 complex-derived ROS is 
not clear. Among those, the most studied are several molecules downstream of the 
TCR signalling pathway, which have been associated with RA and are redox-
sensitive: protein phosphatases ((203) reviewed in (204)), protein tyrosine kinases 
(205) and the linker for activation of T cells (LAT) (206, 207). 
A protein phosphatase, encoded by the gene PTPN22, has been associated with several 
autoimmune diseases, including RA (31). Phosphatases are inhibited by oxidation due 
to the presence of a cysteine in their reactive site (203, 204). 
T cells from the synovium are activated but hyporesponsive to TCR stimulation in 
vitro. This phenotype has been associated with a conformation change of the protein 
tyrosine kinase LCK that occurs in synovial fluid T cells of RA patients but not in 
blood T cells (208). Several kinases have been shown to be activated by ROS but it is 
unclear the role of NOX2 complex-dependent ROS (reviewed in (117)). 
Similarly, hyporesponsiveness to TCR stimulation of RA synovium T cells has been 
linked to oxidation of LAT, which induces its translocation to the cytosol and therefore 
inactivation (206, 207). 
Recently a direct influence of NOX2 and NCF1 on T cell phenotype has been reported. 
Defects in the NOX2 complex enhance production of pro-inflammatory cytokines in 
human CGD leukocytes (189). Also in mouse models of CGD, T cells exhibit increased 
production of IL-17 and IL-23 but decreased IFN-y, IL-10 and TGF-β (209). This 
response has been described as a consequence of a dysfunctional kynurenine pathway 
in the tryptophan catabolism, which suppresses T cells activation (209). However, the 
same pathway is not found affected in human CGD leukocytes (210). In another mouse 
strain lacking NOX2 complex-derived ROS due to a natural occurring SNP in Ncf1, T 
cells produced higher amounts of IFN-γ, TNF-α (paper I), IL-17 (211) and IL-5 (212). 
In rat, a SNP in Ncf1 that decreases ROS production increases numbers of reduced 
protein on the surface of T cells and the arthritogenicity of the cells (197). Recently it 
has been shown how defects in Ncf1 impair development and functionality of T 
regulatory cells (198, 209). 
In both human and rodents, abundant evidence is starting to reveal the regulatory 
molecular mechanisms of NOX2 complex and derived ROS on T cells activity, 
pointing towards a role of ROS in suppression of T cell activation. 
 
NCF1 in RA 
Ncf1 was positionally cloned in 2003 as an arthritis-regulating gene in the pristane–
induced rat model of arthritis, a model of autoimmune arthritis (5). DA rats showed 
lower ROS production and higher severity of the disease compared to the E3 strain 
(5). Out of the three SNPs that differ between the DA and E3 form of Ncf1, one has 
been recently identified as the responsible SNP for causing both the reduced ROS 
production and more severe arthritis (213). This SNP does neither affect localization of 
the protein nor the assembly of the NCF1/NCF2 complex (213), but is likely to operate 
later in the activation cascade of the NOX2 complex. In mice, Ncf1 knock-out animals 
developed a more severe arthritis when injected with intra-articular with zymosan 
(176). A spontaneously occurred mutation that impairs the function of the NCF1 
protein increases arthritis severity, antibody production and pro-inflammatory 
cytokines production in CIA (6, 212, 214), and in peptide-induced arthritis (paper IV). 
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This Ncf1 mutation (Ncf1m1J or Ncf1*/*) facilitates the breaking of tolerance to collagen 
and development of autoimmune arthritis ((215-217) and paper II). 
Recently a copy number variation of the NCF1 gene has been found to be associated 
with RA (151). NCF1 is found phosphorylated in neutrophils from synovial fluid of RA 
patients, while it is not in circulating blood neutrophils. Synovial fluid neutrophils 
produce more ROS and high local levels of TNF-α and IL-8 (169). This observation 
suggests that the NOX2 complex is primed in synovium of RA patients, and it agrees 
with the observation of a chronic NOX2 complex activation in the joints of RA patients 
(167, 168). 
All these observation strongly suggest that the function of NOX2 complex and the 
regulation by NCF1 are important in RA pathogenesis. In animal models, impairment 
of NCF1, and therefore of NOX2 complex-dependent ROS production, increases 
severity and susceptibility to arthritis. This is accompanied by an increased T cells 
activation. Our current hypothesis is that APCs-derived ROS shape the T cell response, 
suppressing a pathogenic autoimmune activity. Paper I investigated this hypothesis and 
confirmed it. 
In humans, recent investigations confirmed the correlation between higher severity of 
autoimmune inflammation in the nervous system and lower NOX2 complex-dependent 
ROS production by leukocytes (218-220). Similar studies performed with RA patients 
are attending. 
Identifying the molecular mechanisms behind the influence of NCF1 in arthritis will 
lead to a deeper understanding of the disease and the development of targeted drugs. 
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PRESENT INVESTIGATION 
Ncf1 was found to be an arthritis-regulating gene in rats and mice: natural occurring 
SNPs in the gene reduced the functionality of the protein and increased the severity of 
arthritis in rat and mouse models (5, 6). An effect of the Ncf1 mutation was the 
increased activation of autoreactive and arthritogenic T cells (5, 6, 197). As neither 
NCF1 expression nor NCF1-dependent oxidative burst was detected in T cells (197, 
199, 202), we hypothesized that ROS produced by other cells would influence the T 
cell phenotype. T cells interact closely with APCs throughout all their life. APCs - a 
classification that includes macrophages, dendritic cells and B cells - express NCF1 and 
are able to produce an NCF1-dependent oxidative burst (140, 199, 221, 222). After 
observing that macrophages were the cells that expressed the highest levels of NCF1 
and produced the most ROS among APCs, we investigated how NCF1-dependent ROS 
by macrophages shaped the adaptive immune response. We found that ROS production 
by macrophages reduced the autoimmune response by decreasing the activation of Th1 
T cells (paper I). We then confirmed that macrophages lacking NCF1-dependent ROS 
production could present antigens and prime an autoimmune response (paper II). NCF1 
is a regulatory component of the NOX2 complex, whose function is vital for anti-
bacterial defence. Neutrophils, the cells with the highest expression of NOX2 complex, 
have been considered the main players in the fight against bacterial infections. We 
could show that NCF1-dependent ROS production by macrophages alone could alone 
efficiently protect the host from bacterial infections (paper III). In the last paper, we 
investigated a new model of arthritis where the disease could be induced by a peptide 
instead of a protein as in CIA. Even in this model, the disease severity was increased by 
the Ncf1 mutation. We characterized the immunological pathways involved in the 
pathogenesis of the arthritis and the features that render the peptide arthritogenic (paper 
IV). 
 
PAPER I 
In paper I we first confirmed that in C57BL/10.Q (B10.Q) mice, the used background 
strain, all APCs expressed NCF1 and were able to produce ROS upon stimulation. The 
level of protein expression and of ROS production was different in different cell types, 
where macrophages were the cells with the highest expression followed by dendritic 
cells and B cells. We chose then to investigate the effect of macrophages oxidative 
burst in vivo. We constructed a transgenic mouse where the functional NCF1 protein 
was expressed under the human CD68 promoter on Ncf1 mutated (Ncf1*/*) 
background. The new strain was named macrophage NCF1 (MN). The expression of 
the MN transgene on Ncf1*/* background restored NCF1 expression and ROS 
production specifically in macrophages. Ncf1*/* MN+ mice immunized with CII in 
CFA developed less severe arthritis and lower titers of anti-CII antibodies than their 
littermates Ncf1*/* MN- and at comparable levels to Ncf1*/+ mice. No differences in 
arthritis score and incidence were observed between Ncf1*/* MN+ and Ncf1*/* MN- 
mice when CAIA, a T cell-independent model of arthritis, was induced. T cells from 
Ncf1*/* MN+ mice produced lower levels of IL-2 and Th1 cytokines after in vitro re-
challenge, when compared to cells from Ncf1*/* MN- mice. In a criss-cross experiment 
where primed T cells and macrophages from Ncf1*/* MN+, Ncf1*/* MN- or Ncf1+/+ 
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(Ncf1 wt) mice were co-cultured in vitro in all possible combinations, ROS producing 
macrophages decreased the proliferation and IL-2 production of T cells, independently 
of the T cell origin. Conversely, IFN-γ production was decreased in all co-cultures 
where T cells originated from the Ncf1*/* MN+ or Ncf1+/+ mice, independently of 
macrophages origin. 
From this study we could conclude that ROS production by macrophages decreases T 
cell activation and Th1 polarization, leading to a limited T cell dependent autoimmune 
outbreak. We could identify a role for macrophage-derived ROS in both education and 
activation of T cells. Macrophage-derived ROS dampens proliferation during re-
challenge, irrespective of the T cells origin, suggesting a short lasting effect of ROS on 
T cells activation. On the contrary, macrophage-derived ROS during selection and 
priming decreases the Th1 response in T cells, indicating a long lasting effect of ROS 
during T cell education. 
 
PAPER II 
In paper II we aimed at investigating whether macrophages could prime arthritogenic T 
cells. We took advantage of the well-characterized CIA model, where the MHC class II 
Aq molecule is associated with susceptibility to disease and Ap with resistance (76, 78). 
This is most likely due to the fact that APCs expressing Aq can process and present the 
immunogen, CII, to T cells while APCs carrying Ap cannot (77). At molecular level, Aq 
binds with higher affinity to the immunodominant T cell epitope than Ap (77). The Ncf1 
mutation can increase the arthritis severity in Aq expressing mice (B10.Q) but could not 
break the resistance to arthritis of Ap expressing C57BL/10.P mice (B10.P), suggesting 
that the pathways altered by Ncf1 mutation could not break the arthritis resistance 
imposed by the MHC. In order to study CII presentation by macrophages we 
constructed a transgenic mouse where the Aq molecule is expressed under the human 
CD68 promoter, considered being specific for macrophages in mouse (223), on the 
B10.P background (Macrophage Aβq: MBQ). We confirmed that in MBQ mice 
macrophages were the only APCs that expressed Aq and could present CII to T cells. In 
order to study the role of Ncf1 during macrophage priming, the Ncf1 mutation was 
inserted. When CIA was induced in MBQ mice, with or without the Ncf1 mutation, 
only the mice carrying the mutated form of Ncf1 developed disease. We therefore 
concluded that macrophages could present CII to T cells and prime them to be 
arthritogenic. This occurs only when NCF1-dependent ROS is impaired, indicating that 
ROS regulates the T cells response at the selection and/or priming stage. 
 
PAPER III 
In paper III we investigated the influence of macrophage specific expression of NCF1 
on the best-known function of the NOX2 complex: antimicrobial defence. The NADPH 
complex was discovered in the ’70s when trying to understand the molecular basis of a 
disease called chronic granulomatous disease (CGD) (154), characterized by recurred 
life threatening infection and a reduced oxidative burst in phagocytes (155-157). 
Mutations in all the subunits of the complex, including NCF1, have been observed in 
CGD patients (158, 159). Ncf1 knockout mice (Ncf1-/-) are affected by spontaneous 
bacterial infections (160) and therefore are often used as a mouse model of CGD. As 
human CGD is most commonly caused by single mutations, we investigated whether 
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the naturally occurring Ncf1 mutated (Ncf1*/*) mouse showed increased susceptibility 
to infections comparably to the human CGD condition. We observed that Ncf1*/* mice 
occasionally developed spontaneous infections in soft tissues and that they were not 
able to resolve the inflammation. We isolated the bacteria from infected areas and 
identified them as Staphylococcus xylosus, the same strain found in Ncf1-/- mice, and S. 
aureus, the most common CGD pathogen. We then confirmed that Ncf1*/* mice were 
more susceptible to these bacterial infections than Ncf1+/+ mice when the bacteria 
were intravenously administered. As neutrophils are the cells that express the highest 
amount of NOX2 complex (and NCF1 protein) and they produce the most prominent 
oxidative burst, they have been extensively studied for their antimicrobial activity and 
considered the main players in the ROS mediated defence against pathogens (2). 
Monocytes and macrophages have an important capacity to phagocytose and kill 
pathogens. They also express the NOX2 complex and produce oxidative burst. We 
wanted to know if monocytes and macrophages alone could control bacterial infections 
via ROS production. Since in both CGD patients and mouse models the NOX2 
complex is deficient in all cells, it was not possible to delineate the specific contribution 
of macrophage NOX2 to host defence in vivo. We took advantage of the MN mouse, 
where functional Ncf1 is encoded under the human CD68 promoter on Ncf1*/* 
background and therefore specifically expressed in monocytes and macrophages, but 
not in neutrophils, to dissect the role of monocytes in antibacterial defence. We could 
show that Ncf1*/* MN+ mice were resistant to induced infections with S. xylosus and 
Burkholderia cepacia, a common pathogen in CGD patients, which were lethal for 
Ncf1*/* MN- mice.  
In this paper we concluded that the naturally occurring mutation in Ncf1 predisposes to 
a CGD-like disease in mice, characterized by the inability to resolve bacterial infection 
and the development of chronic inflammation, ultimately leading to death. We could 
also conclude that monocyte/macrophage restricted expression of NCF1 protected mice 
from lethal infection, therefore highlighting the role of this cell type in the innate 
immunity function of antibacterial defence. 
 
PAPER IV 
In paper IV we investigated a new model of arthritis where the disease is induced with 
a peptide instead of a protein in Ncf1*/* and Ncf1+/+ B10.Q mice. The ultimate goal is 
to understand how NCF1-dependent ROS affects antigen processing and presentation. 
In this paper we characterized the immunological pathways crucial for disease 
development. The peptide used is derived from the glucose-6-phosphate isomerase 
protein (GPI). It was identified as arthritogenic in DBA/1 mice in a screening for GPI 
peptides that would theoretically bind the MHC II H-2q (the same in DBA/1 mice and 
B10.Q mice) (111). The GPI protein was found to be a target of the immune response 
in the spontaneous model of arthritis K/BxN mice, a TCR transgenic mouse where T 
cells recognise peptides derived from the murine GPI protein (96). Immunization with 
human GPI protein leads to severe arthritis on DBA/1 background, but not on B10.Q 
(105, 106). The arthritogenic peptide isolated from the human GPI protein spans from 
amino acid 325 to 339 (hGPI325-339) and has as sequence: H-IWYINCFGCETHAML-
OH (111). 
We first wondered whether the hGPI325-339 peptide could induce arthritis in B10.Q mice 
and whether the severity of the disease was affected by the Ncf1 mutation. We observed 
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that hGPI325-339 peptide induced arthritis in B10.Q mice and the severity of the disease 
was increased by the Ncf1 mutation. We continued by assessing the immunological 
pathways that underlie the pathology of the disease in B10.Q.Ncf1*/* mice. We could 
observe that the hGPI325-339 peptide-induced arthritis was dependent on MHC haplotype 
(with increasing severity according to the haplotype: q>p>r) and on B and T cells, but 
not on C5. Immunization with the peptide induced a specific Th1 and Th17 response 
with antibody production against the hGPI325-339 peptide. T cells and B cells cross-
reacted to the murine (m)GPI325-339 peptide and murine protein. The hGPI325-339 peptide 
differs from mGPI325-339 peptide in two amino acids at positions 331 and 338, 
underlined in the sequence (mGPI325-339: H-IWYINCYGCETHALL-OH). The murine 
peptide was not able to induce arthritis. We could confirm that the amino acid in 
position 331 was the one responsible for the arthritogenicity of the hGPI325-339 peptide. 
At molecular level this could be explained by a higher affinity to MHC of the peptide 
containing phenylalanine (F) compared to the one containing tyrosine (Y). Ncf1*/* 
mutated mice developed a very mild disease after immunization with mGPI325-339 
peptide and could prime anti-mGPI325-339 peptide Th1 and Th17 cells, confirming that 
the mutation in Ncf1 decreases tolerance towards self antigens. 
From this study we concluded that a peptide-induced arthritis could be established in 
B10.Q and B10.Q.Ncf1*/* mice. This disease model shares important features with 
protein-induced arthritis models, as CIA, indicating common pathways in all the 
models. We could confirm a MHC dependency of the disease and that the peptide binds 
MHC II H-2q, as postulated by Iwanami et al, and as it is occurs with CII. The disease 
was dependent on the presence of an intact adaptive immune compartment, as CIA and 
GPI protein-induced arthritis. The immunization with hGPI325-339 in CFA induced 
activation of Th1 and Th17 cells and B cells producing anti-hGPI325-339 IgG, as in the 
other models. T and B cells cross-reacted with the mGPI protein, suggesting this 
protein as a candidate target for autoimmunity in vivo. 
We could dissect the peptide sequence and link the arthritogenicity of the peptide on 
the presence of phenylalanine in position 331 which also increased the binding to MHC 
Aq. 
Finally we could confirm that a mutation in Ncf1 decreased the tolerance level also in 
peptide-induced arthritis, predisposing mice to autoimmunity as observed earlier in 
other models of arthritis (212, 216, 217). 
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CONCLUDING REMARKS AND FUTURE 
PROSPECTIVE 
Finding the mechanisms that explain how a disease-associated gene mediates its effect 
is the main challenge of today’s medical research. Nowadays technical advances allow 
to identify a large number of genes that have a small impact on disease and the task has 
moved from investigating which genes are associated with the disease to how these 
genes operate. Mechanistic studies have the goal to describe “who, where, when, what 
and how” the associated gene influences the disease development. Many of these 
studies can be performed in vitro, using cell lines or tissue extracts. But to get a 
complete 4D picture of the pathologic mechanism animal models of disease are a 
unique and still indispensable tool. They give the possibility to test the function of the 
gene in an in vivo setting that resembles the human situation, even though is not 
identical. Animal models allow to study specifically and to modify all the parameters 
(“who, where, when, what and how”) that are believed to be of importance, most of 
which cannot be altered in the human situation. In this study, animal models allowed to 
assess the relevance of a cell type, macrophages, and of a biochemical process, the 
production of NOX2 complex-dependent ROS, at the same time in several disease 
settings. As a result, we could confirm that macrophages play an essential role in the 
immune system, both in the innate and adaptive responses. They mediate both known 
functions of the NOX2 complex-derived ROS: killing of bacteria and down-regulation 
of T cell mediated inflammation. 
We could also validate a new disease model, a peptide-induced arthritis, that shares 
important characteristics with the human disease and previous models, while being 
characterized by a higher degree of simplicity compared to previous models. 
 
These discoveries set a new starting point and give new tools to investigate the 
molecular pathways underlying arthritis. Since macrophage-derived ROS play an 
important role in inflammation, it is possible to use this transgenic system to study the 
mechanisms regulated by ROS in T cells and/or macrophages. The peptide-induced 
arthritis model will allow a close examination of the features that render a peptide 
arthritogenic, and of the role of ROS in the development of inflammatory response 
towards an antigen. The ultimate goal and hope is to identify pathways and processes 
that can be modified or reverted so to stop the disease progression. 
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